Zacks Investment Research Lowers TAIWAN LIPOSOME/S (NASDAQ:TLC) to Hold

Zacks Investment Research downgraded shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) from a buy rating to a hold rating in a research report sent to investors on Saturday, reports.

According to Zacks, “Taiwan Liposome Company Ltd. is a specialty pharmaceutical company. It focuses on development and commercialization of novel nanomedicines designed to target unmet medical need in pain management, ophthalmology and oncology. The company’s product pipeline consists of TLC599, TLC590, TLC399 and TLC178 which are in clinical stage. Taiwan Liposome Company Ltd. is headquartered in Taipei City, Taiwan. “

A number of other research firms have also commented on TLC. HC Wainwright reaffirmed a buy rating and set a $10.00 price target on shares of TAIWAN LIPOSOME/S in a research report on Monday, May 20th. Robert W. Baird began coverage on TAIWAN LIPOSOME/S in a research report on Thursday, June 20th. They set an outperform rating for the company. Finally, Cantor Fitzgerald set a $11.00 price target on TAIWAN LIPOSOME/S and gave the company a buy rating in a research report on Friday, April 5th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. TAIWAN LIPOSOME/S currently has an average rating of Buy and an average target price of $9.50.

TAIWAN LIPOSOME/S stock opened at $5.20 on Friday. TAIWAN LIPOSOME/S has a 52 week low of $5.02 and a 52 week high of $11.00. The business’s 50-day simple moving average is $5.36. The company has a debt-to-equity ratio of 0.73, a quick ratio of 2.69 and a current ratio of 2.69. The stock has a market capitalization of $161.22 million and a PE ratio of -11.06.

TAIWAN LIPOSOME/S (NASDAQ:TLC) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.19. TAIWAN LIPOSOME/S had a negative return on equity of 150.56% and a negative net margin of 414.31%. The firm had revenue of $5.11 million during the quarter, compared to analysts’ expectations of $3.00 million. Equities research analysts predict that TAIWAN LIPOSOME/S will post -0.79 EPS for the current year.

An institutional investor recently bought a new position in TAIWAN LIPOSOME/S stock. Millennium Management LLC bought a new position in TAIWAN LIPOSOME/S (NASDAQ:TLC) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 109,500 shares of the company’s stock, valued at approximately $602,000. Millennium Management LLC owned about 0.34% of TAIWAN LIPOSOME/S at the end of the most recent quarter. 2.94% of the stock is currently owned by institutional investors.


Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Read More: How to Use a Moving Average for Trading 

Get a free copy of the Zacks research report on TAIWAN LIPOSOME/S (TLC)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for TAIWAN LIPOSOME/S (NASDAQ:TLC)

Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with's FREE daily email newsletter.